Mumbai, May 15 -- Lupin announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New

Drug Application for Rivaroxaban Tablets USP, 10 mg, 15 mg, and 20 mg. Rivaroxaban Tablets are bioequivalent to Xarelto(R) Tablets, 10 mg, 15 mg, and 20 mg, of Janssen Pharmaceuticals. This product will be manufactured at Lupin's Aurangabad facility in India.

Published by HT Digital Content Services with permission from Capital Market....